Literature DB >> 30475230

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.

Matthew S Parsons1, Wen Shi Lee1, Anne B Kristensen1, Thakshila Amarasena1, Georges Khoury1, Adam K Wheatley1,2, Arnold Reynaldi3, Bruce D Wines4, P Mark Hogarth4, Miles P Davenport3, Stephen J Kent1,2,5.   

Abstract

A considerable body of evidence suggests that Fc-dependent functions improve the capacity of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This phenomenon, however, has not been formally tested in robust cell-associated macaque simian-human immunodeficiency virus (SHIV) models with newer-generation BnAbs. We studied both the WT BnAb PGT121 and a LALA mutant of PGT121 (which has impaired Fc-dependent functions) for their ability to protect pigtail macaques from an i.v. high-dose cell-associated SHIVSF162P3 challenge. We found that both WT and LALA PGT121 completely protected all 12 macaques studied. Further, partial depletion of NK cells, key mediators of Fc-dependent functions, did not abrogate the protective efficacy of PGT121 in 6 macaques. Additionally, in animals with established SHIVSF162P3 infection, SHIV viremia levels were equally rapidly reduced by LALA and WT PGT121. Our studies suggest that the potent neutralizing capacity of PGT121 renders the Fc-dependent functions of the Ab at least partially redundant. These findings have implications for Ab-mediated protection from and control of HIV-1 infection.

Entities:  

Keywords:  AIDS vaccine; AIDS/HIV; Immunology

Mesh:

Substances:

Year:  2018        PMID: 30475230      PMCID: PMC6307963          DOI: 10.1172/JCI122466

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Authors:  O Scharf; H Golding; L R King; N Eller; D Frazier; B Golding; D E Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells.

Authors:  Qing Wei; Jackie W Stallworth; Patricia J Vance; James A Hoxie; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Dror Kolodkin-Gal; Sandrine L Hulot; Birgit Korioth-Schmitz; Randi B Gombos; Yi Zheng; Joshua Owuor; Michelle A Lifton; Christian Ayeni; Robert M Najarian; Wendy W Yeh; Mohammed Asmal; Gideon Zamir; Norman L Letvin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

4.  Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.

Authors:  Jinyan Liu; Khader Ghneim; Devin Sok; William J Bosche; Yuan Li; Elizabeth Chipriano; Brian Berkemeier; Kelli Oswald; Erica Borducchi; Crystal Cabral; Lauren Peter; Amanda Brinkman; Mayuri Shetty; Jessica Jimenez; Jade Mondesir; Benjamin Lee; Patricia Giglio; Abishek Chandrashekar; Peter Abbink; Arnaud Colantonio; Courtney Gittens; Chantelle Baker; Wendeline Wagner; Mark G Lewis; Wenjun Li; Rafick-Pierre Sekaly; Jeffrey D Lifson; Dennis R Burton; Dan H Barouch
Journal:  Science       Date:  2016-08-18       Impact factor: 47.728

5.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors:  Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

6.  Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.

Authors:  S L Gooneratne; R J Center; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

7.  Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

Authors:  Lucia Reh; Carsten Magnus; Merle Schanz; Jacqueline Weber; Therese Uhr; Peter Rusert; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2015-07-09       Impact factor: 6.823

Review 8.  Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?

Authors:  Wen Shi Lee; Matthew Sidney Parsons; Stephen John Kent; Marit Lichtfuss
Journal:  Front Immunol       Date:  2015-05-27       Impact factor: 7.561

9.  Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Authors:  Peter B Gilbert; Michal Juraska; Allan C deCamp; Shelly Karuna; Srilatha Edupuganti; Nyaradzo Mgodi; Deborah J Donnell; Carter Bentley; Nirupama Sista; Philip Andrew; Abby Isaacs; Yunda Huang; Lily Zhang; Edmund Capparelli; Nidhi Kochar; Jing Wang; Susan H Eshleman; Kenneth H Mayer; Craig A Magaret; John Hural; James G Kublin; Glenda Gray; David C Montefiori; Margarita M Gomez; David N Burns; Julie McElrath; Julie Ledgerwood; Barney S Graham; John R Mascola; Myron Cohen; Lawrence Corey
Journal:  Stat Commun Infect Dis       Date:  2017-06-06

10.  Elimination of HIV-1-infected cells by broadly neutralizing antibodies.

Authors:  Timothée Bruel; Florence Guivel-Benhassine; Sonia Amraoui; Marine Malbec; Léa Richard; Katia Bourdic; Daniel Aaron Donahue; Valérie Lorin; Nicoletta Casartelli; Nicolas Noël; Olivier Lambotte; Hugo Mouquet; Olivier Schwartz
Journal:  Nat Commun       Date:  2016-03-03       Impact factor: 14.919

View more
  39 in total

1.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

2.  Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV.

Authors:  Yanqin Ren; Maria Korom; Adam R Ward; Ronald Truong; Dora Chan; Szu-Han Huang; Colin M Kovacs; Erika Benko; Jeffrey T Safrit; John Lee; Hermes Garbán; Rebecca Lynch; R Brad Jones
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

Review 3.  Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.

Authors:  Srivamshi Pittala; Kyle S Morrison; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

4.  Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required?

Authors:  Donald Forthal; Andrés Finzi
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808

5.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

6.  Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.

Authors:  Hakimuddin Sojar; Sarah Baron; Jonathan T Sullivan; Meghan Garrett; Marlies M van Haaren; Jonathon Hoffman; Julie Overbaugh; Benjamin J Doranz; Mark D Hicar
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

7.  Recent insights into Fc-mediated effector responses to HIV-1.

Authors:  Margaret C Carpenter; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

8.  Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.

Authors:  Mangaiarkarasi Asokan; Joana Dias; Cuiping Liu; Anna Maximova; Keenan Ernste; Amarendra Pegu; Krisha McKee; Wei Shi; Xuejun Chen; Cassandra Almasri; Wanwisa Promsote; David R Ambrozak; Lucio Gama; Jianfei Hu; Daniel C Douek; John-Paul Todd; Jeffrey D Lifson; Slim Fourati; Rafick P Sekaly; Andrew R Crowley; Margaret E Ackerman; Sung Hee Ko; Divya Kilam; Eli A Boritz; Laura E Liao; Katharine Best; Alan S Perelson; John R Mascola; Richard A Koup
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-20       Impact factor: 11.205

Review 9.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Authors:  Wen Shi Lee; Adam K Wheatley; Stephen J Kent; Brandon J DeKosky
Journal:  Nat Microbiol       Date:  2020-09-09       Impact factor: 17.745

10.  Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates.

Authors:  Lars Hangartner; David Beauparlant; Eva Rakasz; Rebecca Nedellec; Nathanaël Hozé; Katherine McKenney; Mauricio A Martins; Gemma E Seabright; Joel D Allen; Andrea M Weiler; Thomas C Friedrich; Roland R Regoes; Max Crispin; Dennis R Burton
Journal:  Sci Transl Med       Date:  2021-03-17       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.